Now Evaluating Claims Involving Tysabri Patients Diagnosed With Severe Liver Damage or Melanoma
Monday, March 03, 2008
Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. announced that they are evaluating claims of patients treated with the drug Tysabri(r) who have been diagnosed with severe liver damage or melanoma. The announcement comes shortly after the manufacturers of Tysabri, Biogen Idec Inc. (Nasdaq:BIIB) and Elan Corp. plc (NYSE:ELN), warned about reports of liver toxicity in patients treated with the drug following its approval by the Food and Drug Administration, and a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after the drug was administered. Tysabri(r) patients who have been diagnosed with severe cases of liver damage or melanoma are encouraged to visit our section on tysabri for a free legal consultation.
The letter sent to healthcare professionals warning about the risk of liver damage in patients treated with Tysabri(r) is available on the FDA website. An extract of the letter that appeared in the New England Journal of Medicine is available on the NEJM website.
About Tysabri(r)
Tysabri(r), the brand name for natalizumab, is a monoclonal antibody that is approved for the treatment of Multiple Sclerosis (MS) and Crohn's disease. Tysabri(r) was first approved by the FDA in November 2004, but was removed from the market just three months later after several patients were diagnosed with a rare, often fatal opportunistic brain infection called progressive multifocal leukoencephalopathy (PML). The FDA allowed Tysabri back on the market in June 2006 for the treatment of Multiple Sclerosis with revised warnings and strict requirements for close monitoring of patients receiving the drug. Earlier this year, the FDA approved Tysabri for the treatment of Crohn's disease.
Tysabri(r) Litigation Experience
The attorneys at Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. have a track record of both past and present litigation against Biogen Idec and Elan on behalf of Tysabri(r) victims. The firms currently represent the family of a patient who died from an opportunistic infection after receiving Tysabri(r). The case is pending in the U.S. District Court in Boston, Massachusetts (Civil Action No. 07-CA-11840 (DPW)). In 2006, in a highly publicized case, the attorneys at the firms represented the family of a woman who died from PML following Tysabri(r) treatment in state court in Massachusetts. See www.fda.gov/ohrms/dockets/AC/06/slides/2006-4208OPH1-01-MacDonald.ppt; http://news-service.stanford.edu/news/2006/.
Posted under: Dangerous Drugs • Tysabri